Posted by Michael Wonder on 14 Nov 2025
Allterum Therapeutics receives FDA fast track designation for 4A10 in acute lymphoblastic leukaemia
11 November 2025 - Allterum Therapeutics today announced that the US FDA has granted fast track designation for its lead program, 4A10, a monoclonal antibody targeting the interleukin-7 receptor alpha (IL-7Rα; CD127) for the treatment of patients with relapsed or refractory acute lymphoblastic leukaemia.
Allterum previously received orphan drug designation and rare paediatric disease designation for 4A10 in acute lymphoblastic leukaemia, underscoring its potential to address critical unmet needs in paediatric leukaemia.
